Form 4: Director Schwarzentraub Acquires CONMED Corp Stock

Barbara J. Schwarzentraub, a Director at CONMED Corp, reported the acquisition of 668 shares of common stock and 5,772 Restricted Stock Units (RSUs).

Summary

• Director Barbara J. Schwarzentraub acquired 668 shares of CONMED Corp common stock on June 2, 2026.
• The acquisition was made at a price of $0 per share, indicating it was likely a grant or award.
• Schwarzentraub also acquired 5,772 Restricted Stock Units (RSUs) on June 1, 2026, with vesting conditions tied to the company's 2025 Long-Term Incentive Plan.
• These RSUs generally vest 100% after one year.
• Following these transactions, Schwarzentraub beneficially owns 5,012 shares of common stock directly and an additional 1,442 shares indirectly through The Barbara J. Schwarzentraub Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a director's acquisition of stock and RSUs, which can indicate confidence, but it does not provide new financial performance data.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of 668 shares and 5,772 RSUs by a director indicates continued investment and commitment to the company.
• The RSUs are structured to vest over time, aligning the director's incentives with long-term company performance.

Future Outlook

The Restricted Stock Units (RSUs) acquired are subject to vesting conditions, with a general vesting period of 100% after one year, indicating a forward-looking incentive structure tied to continued service and company performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as director stock acquisitions, are closely watched by the market as potential indicators of management's view on the company's valuation and future performance within the medical technology sector.

Stakeholder Impact

• Shareholders: The acquisition of stock by a director may be interpreted as a positive signal of confidence in the company's future, potentially influencing investor sentiment.
• Management: The RSU grants align management's incentives with long-term shareholder value creation through vesting periods.

Next Steps

• RSUs will vest 100% after a one-year period, contingent on the terms of the company's 2025 Long-Term Incentive Plan.
• The acquired common stock is now beneficially owned by the reporting person and potentially her trust.

Key Dates

Keywords

CONMED Corp, CNMD, Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, RSUs, Director, Beneficial Ownership, SEC Filing